Capricor Therapeutics, Inc

(NASDAQ:CAPR)

Latest On Capricor Therapeutics, Inc (CAPR):

Date/Time Type Description Signal Details
2023-05-12 07:12 ESTNewsCapricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 17:36 ESTNewsCapricor Therapeutics GAAP EPS of -$0.31 beats by $0.01, revenue of $2.98M beats by $2.48MN/A
2023-03-16 00:26 ESTNewsCapricor Therapeutics GAAP EPS of -$0.31 beats by $0.03, revenue of $0.96M beats by $0.96MN/A
2023-03-16 00:26 ESTNewsCapricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Call TranscriptN/A
2023-03-14 18:00 ESTNewsCapricor Therapeutics Q4 2022 Earnings PreviewN/A
2023-01-25 14:41 ESTNewsCapricor stock falls amid data for duchenne muscular dystrophy studyN/A
2022-11-11 07:18 ESTNewsCapricor Therapeutics GAAP EPS of -$0.26 beats by $0.05, revenue of $1.59M beats by $1.45MN/A
2022-11-11 07:17 ESTNewsCapricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 21:36 ESTNewsCapricor Therapeutics Q3 2022 Earnings PreviewN/A
2022-08-12 00:03 ESTNewsCapricor stock rises 16% after update on muscular dystrophy treatment, Q2 resultsN/A
2022-08-11 07:06 ESTNewsCapricor Therapeutics GAAP EPS of -$0.29 misses by $0.03N/A
2022-08-11 07:06 ESTNewsCapricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call TranscriptN/A
2022-08-09 20:06 ESTNewsCapricor Therapeutics Q2 Earnings PreviewN/A
2022-06-28 01:00 ESTNewsCapricor posts statistically significant data for DMD candidate in open-label trialN/A
2022-05-11 01:15 ESTNewsCapricor Therapeutics GAAP EPS of -$0.32N/A
2022-05-11 01:15 ESTNewsCapricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q1 2022 Results - Earnings Call TranscriptN/A
2022-03-28 16:40 ESTNewsCapricor Therapeutics down 24% following COVID-19 mid-stage trial results (updated)N/A
2022-03-11 08:26 ESTNewsCapricor Therapeutics, Inc. (CAPR) CEO Linda Marban On Q4 2021 Results - Earnings Call TranscriptN/A
2022-01-25 10:04 ESTNewsCapricor jumps 12% after CAP-1002 commercialization deal in U.S. for treatment of DMDN/A
2021-12-13 16:39 ESTNewsCapricor Therapeutics provides key updates on its COVID-19 vaccine programsN/A
2021-11-10 04:09 ESTNewsCapricor Therapeutics EPS beats by $0.06N/A
2021-11-10 04:08 ESTNewsCapricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-09 05:10 ESTNewsCapricor Therapeutics Q3 2021 Earnings PreviewN/A
2021-09-25 19:24 ESTNewsCapricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial ResultN/A
2021-09-24 23:37 ESTNewsCapricor jumps 17% on positive CAP-1002 data from mid-stage duchenne muscular dystrophy studyN/A
2021-09-02 16:11 ESTNewsCapricor shares up 6 % as it will present final data on muscular dystrophy candidate late SeptemberN/A
2021-08-13 10:16 ESTNewsCapricor Therapeutics EPS beats by $0.02, misses on revenueN/A
2021-08-13 10:15 ESTNewsCapricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-20 22:51 ESTNewsCapricor Therapeutics slumps 9% on $75M stock offeringN/A
2021-04-30 07:24 ESTNewsCapricor shares rise on license agreement with Johns Hopkins UniversityN/A
2021-03-18 04:19 ESTFinancialsCompany financials have been released.Neutral
2021-03-13 03:16 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 07:18 ESTEarnings EstimateAn EPS average of -$1.07 is estimated for the 2022 year.Sell
2021-03-12 00:43 ESTNewsCapricor Therapeutics EPS misses by $0.01N/A
2021-03-12 00:43 ESTNewsCapricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-09 13:49 ESTNewsCapricor Therapeutics updates on COVID-19 vaccine pre-clinical studyN/A
2021-02-10 08:09 ESTNewsCapricor Therapeutics - Shockingly Undervalued With Imminent Catalysts In PlayN/A
2021-02-01 10:47 ESTNewsCapricor signs intellectual property license for COVID-19 serology test platformN/A
2021-01-25 03:17 ESTAnalyst RatingThe Analyst Target Price has increased from $10.5 to $12.Buy
2021-01-20 01:02 ESTNewsCapricor announces positive findings from collaboration with Cedars-Sinai Medical Center researchersN/A
2021-01-12 20:54 ESTNewsCapricor and Lonza tie up in DMD developmentN/A
2020-12-13 03:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:54 ESTNewsDosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19N/A
2020-11-18 03:20 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 03:25 ESTFinancialsCompany financials have been released.Neutral
2020-11-15 11:31 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 03:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 22:56 ESTNewsCapricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-12 19:06 ESTNewsCapricor Therapeutics reports Q3 resultsN/A
2020-11-01 17:26 ESTFinancialsCompany financials have been released.Neutral

About Capricor Therapeutics, Inc (CAPR):

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

CAPR Quotes by TradingView

See Advanced Chart

General

  • Name Capricor Therapeutics, Inc
  • Symbol CAPR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:10
  • Last Split Date2019-06-05
  • Fiscal Year EndDecember
  • IPO Date2007-02-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.capricor.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 149.52
  • Price/Book (Most Recent Quarter) 4.13
  • Enterprise Value Revenue 190.86
  • Enterprise Value EBITDA 0.03
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.00
  • Next Year EPS Estimate -$1.06
  • Operating Margin -4413%
  • Return on Assets -37%
  • Return on Equity -78%
  • Revenue 310250
  • Earnings Per Share -$3.74
  • Revenue Per Share $0.02
  • Gross Profit -8146750
  • Quarterly Earnings Growth -74%
View More

Highlights

  • Market Capitalization 118.78 million
  • EBITDA -11929662
  • Analyst Target Price $12
  • Book Value Per Share $1.37
View More

Share Statistics

  • Shares Outstanding 22.8 million
  • Shares Float 19.99 million
  • % Held by Insiders 253%
  • % Held by Institutions 6.2%
  • Shares Short 345150
  • Shares Short Prior Month 489136
  • Short Ratio 0.36
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 6.47
  • 52 Week High $12.32
  • 52 Week Low $0.96
  • 50 Day Moving Average 6.37
  • 200 Day Moving Average 5.05
View More

Dividends

  • Dividend Date 2019-06-05
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Capricor Therapeutics, Inc (CAPR) Dividend Calendar:

CAPR's last dividend payment was made to shareholders on June 5, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Capricor Therapeutics, Inc (CAPR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.21-$0.20-5%
2020-09-302020-11-12$N/A-$0.20-$0.3745.95%
2020-06-302020-08-06$N/A-$0.23-$0.3432.35%
2020-03-312020-05-13$185693-$0.30-$0.3616.67%
2019-12-312020-03-18$222100-$0.34-$0.340%
2019-09-302019-11-07$142071-$0.43-$0.6836.76%
2019-06-302019-08-06$410353-$0.59-$0.8026.25%
2019-03-312019-05-13$230504-$0.80-$1.1027.27%
2018-12-312019-03-28$648082-$1.10-$1.6031.25%
2018-09-302018-11-13$219247-$1.40-$1.453.45%
2018-06-302018-08-09$403960-$1.40-$1.25-12%
2018-03-312018-05-10$400066-$1.40-$1.20-16.67%
2017-12-312018-03-14$475000$4.20-$1.00520%
2017-09-302017-11-08$314000-$1.20-$1.9036.84%
2017-06-302017-08-10$996000-$1.60-$1.8011.11%
2017-03-312017-05-15$881000-$1.70-$1.50-13.33%
2016-12-312017-03-15$907000-$2.10-$2.7022.22%
2016-09-302016-11-10$747000-$2.90-$2.65-9.43%
2016-06-302016-08-15$1.13 million-$2.60-$2.40-8.33%
2016-03-312016-05-12$1.22 million-$2.60-$1.90-36.84%
2015-12-312016-03-17$1.12 million-$2.10-$1.90-10.53%
2015-09-302015-11-12$1.32 million-$0.18-$0.2630.77%
2015-06-302015-08-13$1.29 million-$0.19-$0.2626.92%
2015-03-312015-05-12$1.79 million-$0.23-$0.14-64.29%
2014-12-312015-03-16$1.4 million-$0.16-$0.13-23.08%
2014-09-302014-11-14$1.3 million-$0.13-$0.2240.91%
2014-06-302014-08-14$1.04 million-$1.31
2014-03-312014-05-15$1.04 million-$1.04
2013-12-312014-03-17$503233-$6.39
2013-09-302013-11-15$80000-$4.02
2013-06-302013-08-15$190000-$6.94
2013-03-312013-06-21$233000-$5.61
2012-12-312013-03-12$2.03 million-$2.39
2012-09-302012-11-12$-2423235-$6.57
2012-06-302012-08-13$N/A-$4.11
2012-03-312012-05-15$195500-$20.00-$15.00-33.33%
2011-12-312012-03-13-$22.29
2011-09-302011-11-14$813000-$15.00-$7.50-100%
2011-06-302011-08-15$346000-$15.00-$5.00-200%
2011-03-312011-05-16-$15.00-$10.00-50%
2010-12-312011-03-14-$10.00-$21.6753.85%
2010-09-302010-11-12-$25.00-$23.33-7.16%
2010-06-302010-08-16-$25.00-$33.3324.99%
2010-03-312010-05-14-$35.00-$28.33-23.54%
2009-12-312010-03-03-$30.00-$25.00-20%
2009-09-302009-11-12-$40.00-$25.00-60%
2009-06-302009-08-13-$50.00-$37.50-33.33%
2009-03-312009-05-14-$35.00-$58.3340%
2008-12-312009-03-09-$60.00-$65.007.69%
2008-09-302008-11-13-$70.00-$78.3310.63%
2008-06-302008-08-14-$80.00-$57.50-39.13%
2008-03-312008-05-15-$65.00-$55.00-18.18%
2007-12-312008-03-13-$50.00-$95.0047.37%
2007-09-302007-11-28-$173.63
2006-12-312006-12-31-$6.69
2006-09-302006-09-30-$23.16
2006-06-302006-06-30-$5.98
2006-03-312006-03-31-$4.79
2005-09-302005-09-30-$2.28
2005-06-302005-06-30-$1.95
2005-03-312005-03-31-$3.57
2004-12-312004-12-31-$6.14
2004-09-302004-09-30-$2.33
2004-06-302004-06-30-$1.90
2004-03-312004-03-31-$1.64
2003-12-312003-12-31-$3.57
2003-09-302003-09-30-$0.06
2003-06-302003-06-30-$4.61
2003-03-312003-03-31-$2.46
2002-12-312002-12-31-$2.50
2002-09-302002-09-30-$5.67
2002-06-302002-06-30-$6.25

Capricor Therapeutics, Inc (CAPR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A 1.16 million 828749
Income Before Tax N/A N/A N/A -2.08 million -1.47 million
Selling General Administrative N/A N/A N/A 1.14 million 876720
Gross Profit N/A N/A N/A N/A 222100
Ebit N/A N/A N/A -2.07 million -1.48 million
Operating Income N/A N/A N/A -2.11 million -1.48 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 185693 222100
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 22690 13951
Net Income From Continuing Operations N/A N/A N/A -2.08 million -1.47 million
Net Income Applicable to Common Shares -4.18 million -3.91 million -3.48 million N/A -1.47 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities N/A N/A 426904 N/A N/A
Total Cash Flow from Investing Activities N/A N/A 5.99 million N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities N/A N/A 149635 N/A N/A
Change in Cash N/A N/A N/A N/A N/A
Total Cash from Operating Activities N/A N/A -1.22 million N/A N/A
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A N/A 287807 N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A 5.78 million 5.47 million N/A N/A
Total Stockholder Equity N/A 30.41 million 31.65 million N/A N/A
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A 36.19 million 37.13 million N/A N/A
Common Stock 20577 20212 N/A 9189 N/A
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -88.04 million -83.86 million N/A -76.47 million N/A
Other Liabilities 3.38 million 3.38 million N/A 3.38 million N/A
Other Assets 88701 88701 N/A 107380 N/A
Cash N/A N/A N/A N/A N/A
Total Current Liabilities 2.97 million 2.28 million N/A N/A N/A
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 850847 603719 N/A 410913 N/A
Total Current Assets 33.68 million 35.49 million 36.25 million N/A N/A
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 28.2 million 30.4 million 9.59 million 9.59 million N/A
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 2.72 million 2.06 million N/A N/A N/A

Capricor Therapeutics, Inc (CAPR) Chart:

Capricor Therapeutics, Inc (CAPR) News:

Below you will find a list of latest news for Capricor Therapeutics, Inc (CAPR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Capricor Therapeutics, Inc (CAPR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-202.512.6CALL1 37205.43TRUE-0.2-0.02
2024-12-20511.72CALL1 1248185.81TRUE1.370.13
2024-12-207.57.5CALL5 355132.97TRUE-0.54-0.07
2024-12-20105.36CALL52 317107.19TRUE-1.14-0.18
2024-12-2012.53.8CALL29 266112.5TRUE-1-0.21
2024-12-20153.38CALL10 67119.73TRUE0.080.02
2024-12-2017.52.65CALL5132 1124.1FALSE0.70.36
2024-12-20201.78CALL179 165115.56FALSE-0.47-0.21
2024-12-2022.52.32CALL2 0124.59FALSE2.320
2024-12-20251.27CALL5 0127.86FALSE1.270
2024-12-20300.8CALL1 0128.92FALSE0.80
2024-12-202.50.05PUT8 342197.22FALSE00
2024-12-2050.15PUT0 4990FALSE00
2024-12-207.50.45PUT5 63136.8FALSE-0.1-0.18
2024-12-20101.3PUT40 166143.53FALSE00
2024-12-2012.52.5PUT156 102146.51FALSE00
2024-12-20154.06PUT16 8151.25FALSE0.160.04
2024-12-2017.55.4PUT2 0139.27TRUE5.40
2024-12-20200PUT0 0148.42TRUE00
2024-12-2022.50PUT0 0149.05TRUE00
2024-12-20250PUT0 0157.12TRUE00
2024-12-20300PUT0 0157.93TRUE00
2025-01-172.510.1CALL0 12127.04TRUE00
2025-01-1759.45CALL972 9149158.27TRUE-0.65-0.06
2025-01-177.57.4CALL1181 628698.17TRUE-0.9-0.11
2025-01-17105.3CALL0 281109.57TRUE00
2025-01-1712.54.4CALL7 1097116.64TRUE-0.9-0.17
2025-01-17153.8CALL5 167116.04TRUE-0.35-0.08
2025-01-1717.53.2CALL19 4123.28FALSE-0.4-0.11
2025-01-17202.2CALL314 122119.9FALSE-0.7-0.24
2025-01-1722.51.95CALL35 0119.81FALSE1.950
2025-01-17250CALL0 0125.22FALSE00
2025-01-17300CALL0 0127.64FALSE00
2025-01-172.50.14PUT559 2146206.75FALSE0.040.4
2025-01-1750.3PUT107 9256155.21FALSE-0.05-0.14
2025-01-177.50.85PUT112 1187148.28FALSE-0.05-0.06
2025-01-17101.6PUT100 17138.41FALSE-0.1-0.06
2025-01-1712.53.2PUT8 25153.05FALSE0.10.03
2025-01-17154.7PUT0 2142.21FALSE00
2025-01-1717.56.6PUT16 8139.45TRUE0.30.05
2025-01-17206.6PUT3 3147.32TRUE-1.7-0.2
2025-01-1722.50PUT0 0146.75TRUE00
2025-01-17250PUT0 0147.91TRUE00
2025-01-17300PUT0 0150.11TRUE00
2025-03-212.512.53CALL115 148205.68TRUE-0.37-0.03
2025-03-21510.18CALL139 58888.16TRUE-0.32-0.03
2025-03-217.57.96CALL41 247782.99TRUE0.410.05
2025-03-21107CALL137 421102.84TRUE0.20.03
2025-03-2112.55.6CALL30 69112.22TRUE-0.2-0.03
2025-03-21154CALL92 255109.35TRUE-0.77-0.16
2025-03-2117.53.6CALL37 14106.85FALSE-0.2-0.05
2025-03-21203.25CALL168 166113.93FALSE-0.25-0.07
2025-03-2122.50CALL0 0112.43FALSE00
2025-03-21250CALL0 0118.5FALSE00
2025-03-21301.75CALL280 0115.58FALSE1.750
2025-03-212.50.25PUT0 220FALSE00
2025-03-2150.6PUT11 85152.99FALSE00
2025-03-217.51.2PUT0 36137.49FALSE00
2025-03-21102.25PUT1 21135.47FALSE-0.1-0.04
2025-03-2112.55.1PUT0 3135.28FALSE00
2025-03-21155.2PUT7 9136.28FALSE00
2025-03-2117.50PUT0 0135.52TRUE00
2025-03-21208.41PUT25 36136.6TRUE-0.37-0.04
2025-03-2122.50PUT0 0138.82TRUE00
2025-03-21250PUT0 0143.93TRUE00
2025-03-21300PUT0 0144.89TRUE00

Latest CAPR Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST62$3.88
Jun 13, 2022 7:58 PM EST5$3.8
Jun 13, 2022 7:59 PM EST100$3.8
Jun 13, 2022 7:59 PM EST100$3.79
Jun 13, 2022 7:59 PM EST50$3.79

Capricor Therapeutics, Inc (CAPR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920074227/0001104659-20-074227-index.htm
2018-10-31UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1133869/000000000018034036/0000000000-18-034036-index.htm
2019-12-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1133869/000000000019016215/0000000000-19-016215-index.htm
2020-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1133869/000000000020004293/0000000000-20-004293-index.htm
2019-12-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1133869/000091957419007837/0000919574-19-007837-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465919061080/0001104659-19-061080-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000110465919061773/0001104659-19-061773-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465919063785/0001104659-19-063785-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465919064252/0001104659-19-064252-index.htm
2019-12-05S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1133869/000110465919070066/0001104659-19-070066-index.htm
2019-12-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1133869/000110465919072396/0001104659-19-072396-index.htm
2019-12-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1133869/000110465919072626/0001104659-19-072626-index.htm
2019-12-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1133869/000110465919072629/0001104659-19-072629-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465919073161/0001104659-19-073161-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465919073600/0001104659-19-073600-index.htm
2019-12-19424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1133869/000110465919074049/0001104659-19-074049-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465919074247/0001104659-19-074247-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465919074513/0001104659-19-074513-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465919074514/0001104659-19-074514-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465919074516/0001104659-19-074516-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022098/0001104659-20-022098-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022099/0001104659-20-022099-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022100/0001104659-20-022100-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022101/0001104659-20-022101-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022102/0001104659-20-022102-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022103/0001104659-20-022103-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022104/0001104659-20-022104-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022105/0001104659-20-022105-index.htm
2020-02-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920022110/0001104659-20-022110-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920031538/0001104659-20-031538-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920034994/0001104659-20-034994-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920035320/0001104659-20-035320-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920038468/0001104659-20-038468-index.htm
2020-03-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/0001104659-20-039272-index.htm
2020-04-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920047790/0001104659-20-047790-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920056292/0001104659-20-056292-index.htm
2020-05-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1133869/000110465920056303/0001104659-20-056303-index.htm
2020-05-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1133869/000110465920058189/0001104659-20-058189-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920058192/0001104659-20-058192-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920060449/0001104659-20-060449-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920060930/0001104659-20-060930-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920061570/0001104659-20-061570-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920062419/0001104659-20-062419-index.htm
2020-05-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1133869/000110465920062458/0001104659-20-062458-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000110465920062698/0001104659-20-062698-index.htm
2020-05-19424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1133869/000110465920063822/0001104659-20-063822-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920066994/0001104659-20-066994-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071410/0001104659-20-071410-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071413/0001104659-20-071413-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071415/0001104659-20-071415-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071417/0001104659-20-071417-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071419/0001104659-20-071419-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071420/0001104659-20-071420-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071421/0001104659-20-071421-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071423/0001104659-20-071423-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920071426/0001104659-20-071426-index.htm
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920074227/0001104659-20-074227-index.htm
2020-07-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920087909/0001104659-20-087909-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920091413/0001104659-20-091413-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000110465920092415/0001104659-20-092415-index.htm
2020-08-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000110465920098381/0001104659-20-098381-index.htm
2020-09-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000110465920109138/0001104659-20-109138-index.htm
2017-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417053252/0001144204-17-053252-index.htm
2017-10-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1133869/000114420417053253/0001144204-17-053253-index.htm
2017-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420417053990/0001144204-17-053990-index.htm
2017-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417057263/0001144204-17-057263-index.htm
2017-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000114420417058512/0001144204-17-058512-index.htm
2017-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417059277/0001144204-17-059277-index.htm
2017-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417061266/0001144204-17-061266-index.htm
2017-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417063248/0001144204-17-063248-index.htm
2017-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417064330/0001144204-17-064330-index.htm
2017-12-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420417065088/0001144204-17-065088-index.htm
2018-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000266/0001144204-18-000266-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000853/0001144204-18-000853-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000854/0001144204-18-000854-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000856/0001144204-18-000856-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000857/0001144204-18-000857-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000859/0001144204-18-000859-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000860/0001144204-18-000860-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000861/0001144204-18-000861-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000862/0001144204-18-000862-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000863/0001144204-18-000863-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000864/0001144204-18-000864-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000865/0001144204-18-000865-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418000868/0001144204-18-000868-index.htm
2018-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418005594/0001144204-18-005594-index.htm
2018-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418009043/0001144204-18-009043-index.htm
2018-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418014063/0001144204-18-014063-index.htm
2018-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418014635/0001144204-18-014635-index.htm
2018-03-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1133869/000114420418016468/0001144204-18-016468-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418022479/0001144204-18-022479-index.htm
2018-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418025173/0001144204-18-025173-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418027107/0001144204-18-027107-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000114420418027786/0001144204-18-027786-index.htm
2018-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418033770/0001144204-18-033770-index.htm
2018-07-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420418039922/0001144204-18-039922-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418043267/0001144204-18-043267-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000114420418043686/0001144204-18-043686-index.htm
2018-10-24S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1133869/000114420418055035/0001144204-18-055035-index.htm
2018-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418056889/0001144204-18-056889-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418059340/0001144204-18-059340-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000114420418059980/0001144204-18-059980-index.htm
2018-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420418066148/0001144204-18-066148-index.htm
2019-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419000167/0001144204-19-000167-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419002173/0001144204-19-002173-index.htm
2019-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419005129/0001144204-19-005129-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419016629/0001144204-19-016629-index.htm
2019-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1133869/000114420419016787/0001144204-19-016787-index.htm
2019-04-0110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1133869/000114420419017194/0001144204-19-017194-index.htm
2019-04-19PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419020402/0001144204-19-020402-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419022029/0001144204-19-022029-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419025600/0001144204-19-025600-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000114420419026041/0001144204-19-026041-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419029338/0001144204-19-029338-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419029669/0001144204-19-029669-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419031589/0001144204-19-031589-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419034627/0001144204-19-034627-index.htm
2019-07-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1133869/000114420419034690/0001144204-19-034690-index.htm
2019-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419034770/0001144204-19-034770-index.htm
2019-07-17S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1133869/000114420419034954/0001144204-19-034954-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419035262/0001144204-19-035262-index.htm
2019-07-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1133869/000114420419035263/0001144204-19-035263-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419037875/0001144204-19-037875-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1133869/000114420419038387/0001144204-19-038387-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419038994/0001144204-19-038994-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419038995/0001144204-19-038995-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419038996/0001144204-19-038996-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419038997/0001144204-19-038997-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419038998/0001144204-19-038998-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419038999/0001144204-19-038999-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419039000/0001144204-19-039000-index.htm
2019-08-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1133869/000114420419039001/0001144204-19-039001-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419040654/0001144204-19-040654-index.htm
2019-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419042160/0001144204-19-042160-index.htm
2019-08-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1133869/000114420419042161/0001144204-19-042161-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1133869/000114420419047446/0001144204-19-047446-index.htm
2019-07-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1133869/999999999519001637/9999999995-19-001637-index.htm
2019-12-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1133869/999999999519002841/9999999995-19-002841-index.htm
2020-05-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1133869/999999999520001205/9999999995-20-001205-index.htm
2018-04-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1133869/999999999718004982/9999999997-18-004982-index.htm
2018-08-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1133869/999999999718007502/9999999997-18-007502-index.htm

Capricor Therapeutics, Inc (CAPR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Capricor Therapeutics, Inc (CAPR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 253%
Institutional Ownership: 620%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-10-23Louis ManzoDirectorBuy20,748.000.163,319.68159,132.00https://www.sec.gov/Archives/edgar/data/1133869/000114420417053990/0001144204-17-053990-index.htm
2019-12-17Frank LitvackDirectorBuy20,391.0020,391.00https://www.sec.gov/Archives/edgar/data/1133869/000110465919074516/0001104659-19-074516-index.htm
2017-12-22Rachel SmithVice President of R&DBuy20,748.000.163,319.6820,748.00https://www.sec.gov/Archives/edgar/data/1133869/000114420418000868/0001144204-18-000868-index.htm
2019-12-17David B MusketDirectorBuy20,391.0022,891.00https://www.sec.gov/Archives/edgar/data/1133869/000110465919074514/0001104659-19-074514-index.htm
2019-12-17Louis ManzoDirectorBuy20,391.0036,304.00https://www.sec.gov/Archives/edgar/data/1133869/000110465919074513/0001104659-19-074513-index.htm
2020-09-24Louis ManzoDirectorBuy8,299.003.7030,706.3044,603.00https://www.sec.gov/Archives/edgar/data/1133869/000110465920109138/0001104659-20-109138-index.htm
2020-07-27Linda MarbanCHIEF EXECUTIVE OFFICERBuy41,497.003.70153,538.9062,367.00https://www.sec.gov/Archives/edgar/data/1133869/000110465920087909/0001104659-20-087909-index.htm